User-generated discontent: patents, gender, and innovation

The NYT has a fascinating story about innovation, menstruation, and the challenges of seeking backing for a project that combines the two.

from Blogger http://ift.tt/25AEJ1E

Posted in Uncategorized | Tagged , , , | Leave a comment

Smokeless, no fire: tobacco advertising & TM claims dismissed

VMR Products, LLC v. V2H ApS, 2016 WL 1177834, No.
2:13–cv–7719 (C.D. Cal. Mar. 18, 2016)
 
VMR makes electronic cigarettes under the federally
registered trademarks V2CIGS and V2. V2H ApS is a Danish tobacco company that makes
a smokeless tobacco product called “snus” under the name V2TOBACCO, and V2
Tobacco A/S is its wholly owned distributor subsidiary. The parties have
litigated cases in Denmark, Sweden, and the Southern District of Florida, and
have opposed each other’s applications to register their trademarks in both the
United States and Europe.
 
VMR alleged that defendants infringed its marks with their
V2TOBACCO product through advertising on http://www.v2tobacco.com; there was no
evidence that defendants’ snus purchased from US stores bore the mark
V2TOBACCO, but US consumers could buy the snus through third-party online
stores, which were accessible by clicking on links available on the website,
and this snus bore the mark V2TOBACCO “[a]t the bottom of [the] tin.”  This sufficed as use in commerce.
 
The court dismissed likely confusion claims based on VMR’s
V2CIGS mark.  VMR previously sought a
declaratory judgment that its V2CIGS didn’t infringe V2 TOBACCO, alleging in
its complaint that there was no likelihood of confusion; that the marks were
different; and that the products were different.  VMR was therefore estopped from arguing to
the contrary; the court also applied the Sleekcraft
factors.
 
Strength: There was no evidence that V2CIGS had been
registered without a showing of secondary meaning, so there was no presumption
of inherent distinctiveness; there was also no evidence about inherent
distinctiveness or descriptiveness either way, so strength was neutral;
likewise there was no evidence about defendants’ intent.  VMR was estopped from arguing that the goods
and the marks were similar; it submitted no admissible evidence of actual
confusion; the parties both advertise on websites, but Network Automation says that’s not important; there was no evidence
that any of the parties’ products are sold in the same or even similar stores; there
was no evidence that either party had plans to expand into the other’s market; and
defendants offered evidence that tobacco products are legally required to be
maintained by retailers under lock and key, and argued that therefore consumers
exercise a degree of care in purchasing tobacco products.  Confusion was not likely with respect to the
V2CIGS mark.
 
VMR also argued that defendants made “illegal, literally
false and/or misleading” statements that the raw material in their snus product
is selected on the basis of a “low level of Nitrosamines” on their website and
in their product catalog. The Tobacco Control Act precludes the introduction
into interstate commerce of any modified risk tobacco product unless the FDA
has issued an order that the product may be commercially marketed.  VMR contended that the “low” levels of nitrosamines
claim advertised snus as a modified risk tobacco product without FDA approval.
 
First, the court found that V2H could be held liable for the
website statements: it was the registrant and owner of http://www.v2tobacco.com; had
previously removed content from the website; and was the “parent company” of V2
Tobacco.
 
Second, the court addressed standing: Under Lexmark, a plaintiff’s claim must fall within
the “zone of interest” of the statute, and the plaintiff must have experienced
“economic or reputational injury” that is proximately caused by the defendant’s
deceptive advertising.  VMR showed that
the parties were competitors in the tobacco market, but offered no evidence of injury
proximately caused by the allegedly false statements. VMR argued that it would
be harmed if an adult smoker, who wanted to purchase a smokeless nicotine
product, relied on defendants’ alleged false advertising to buy snus instead of
VMR’s electronic cigarettes.  However,
there was no requirement that a plaintiff prove injury if it sought only
injunctive relief.  (Something feels
weird about this, but ok.)  Thus, VMR had
standing to pursue its claims, but not standing to seek “additional ancillary
relief that would require proof of injury” such as damages for lost sales.
 
VMR argued that defendants’ statements that their snus
contains low levels of nitrosamines were “literally false” because (1) the statements
 equated to advertising the snus as a
“modified risk tobacco product” under the Act; (2) the Tobacco Control Act
defines “modified risk tobacco products” as those tobacco products that are
used to reduce the harm or risk of tobacco-related diseases associated with
commercially marketed tobacco products; (3) the FDA has not approved the snus
as a “modified risk tobacco product”; and therefore, (4) defendants’
advertisements violate the Tobacco Control Act.  (This doesn’t seem very “literal” to me, given
the chain of inferences required.  It
also seems like a preclusion problem, given the interpretation necessary to
make this into an issue of falsity instead of a violation of the Tobacco
Control Act itself.)  The court found
that this was not a literally false claim given that the FDA hadn’t yet
approved [hunh?] the use of “low” to describe the level of nitrosamines in the
product.
 
Defendants offered evidence that their snus did, in fact,
have low levels of nitrosamines.  VMR
offered no evidence of misleadingness, or of materiality.  Nor would the court presume injury given the
absence of comparative advertising here: “the alleged injury accrues equally to
all competitors.”  Summary judgment for
defendants.

from Blogger http://ift.tt/1PDDS4F

Posted in Uncategorized | Tagged , , | Leave a comment

Bar review question: is this false advertising?

Themis Bar Review, LLC v. Kaplan, Inc., 2016 WL 1162624, No.
14-cv-00208 (S.D. Cal. Mar. 24, 2016)
 
Themis, a relative newcomer to the bar review business,
advertised its students’ bar passage rates; a 2013 ad listed passage rates for
2012.  The left column of the ad listed a
jurisdiction, and the two columns to the right showed Themis’ students’ passage
rates for that jurisdiction and the overall state passage rate for that
jurisdiction. At the top of both of those columns was a small asterisk,
corresponding to fine print language reading “Based on Themis first-time takers
who completed 75% or more of their course assignments and on state bar exam
first-time takers.”  Themis filed a
declaratory judgment action and Kaplan counterclaimed for false advertising.
 

Ad as shown in Themis’ declaratory judgment action

Ad as shown in Kaplan’s counterclaim

The court declined to grant cross-motions for summary
judgment.  Themis argued that Kaplan’s
claim was moot because Kaplan sought only injunctive relief and Themis
permanently ceased circulating the relevant ad. But voluntary cessation doesn’t
guarantee mootness, and Themis failed to provide adequate assurances it wouldn’t
run similar ads in the future.  Its CEO
said that it voluntarily changed the format “to make the explanation larger and
more prominent, in the hopes of eliminating any argument over the issue, and
because I favor full disclosure to students choosing between bar exam
providers.”  But a present intent that
could later change isn’t enough.
 
Kaplan argued that the pass rate was literally false, even
coupled with the footnote, because Themis’ data collection methods were
problematic. The court rejected a literal falsity argument based only on the
main text, because “the proper focus is on the advertisement as a whole rather
than an isolated section. Thus, the pass rates are literally false only if they
are inaccurate with respect to the population defined in the footnote: first
time takers who complete 75% or more of the course.”  RT: This reasoning wrongly assumes that the
ad, taken as a whole, actually conveys the message in the footnote to
consumers.  If the footnote doesn’t work
as a disclosure, then Themis shouldn’t get to convert a literal falsity claim
into a more difficult to prove implicit falsity claim by including an element
in the ad that consumers don’t actually perceive as part of the ad context.

As to the footnote-modified claim, Kaplan submitted an expert report concluding
that Themis’ practice of individually contacting students in states that do not
publish pass lists is problematic. Self-reporting “may result in a systematic
response bias such that students who failed the exam might be ashamed of the
fact and therefore lie when asked whether they passed.” Themis argued that
there wouldn’t be misreporting because (1) law students are honest, and (2) it
was in students’ self-interest to report failure because they could get a free
repeat course if they failed.  A
reasonable jury could go either way on this.
 
Likewise, as for the misleadingness claim, summary judgment
was inappropriate.  Law students are the
relevant audience.  Kaplan’s survey gave
the ad to 331 current law students, allowed them to look at it for as long as
they wanted, and then took it away from them before asking various questions. The
test group received the actual Themis ad. The control group received a modified
version that displayed the footnote text more prominently.

Kaplan control ad with disclosure in column text

Both groups were
asked whether the pass rates on the ad represented all Themis test takers or
only a certain subgroup of test takers. In the test group, 15.7% of the
students answered correctly and 69.3 % answered incorrectly. In the control
group, 64.8% of students answered correctly and only 17.6% answered
incorrectly.


Themis’ study was essentially the same, except that it didn’t use a control
group and allowed respondents to keep the ad and refer to it while answering
the questions.  And it tested two
different ads with significantly more prominent footnotes.  (So, completely different.) About 84.5% of the
801 students tested correctly answered that the pass rates referred to a
certain subgroup of Themis students, while about 12% incorrectly said that the
pass rates covered the entire population of Themis students.
 

Ad tested by Themis

Another ad tested by Themis

Themis argued that “in high-level involvement purchasing
decisions such as choosing a bar prep company, a reading test, where the
subject can reference the ad while answering questions, is more appropriate
than a memory test,” given that humans have bad short-term memories.  Kaplan responded that memory wasn’t the issue;
if a student noticed the footnote, short-term memory issues wouldn’t prevent them
from answering correctly a very short time later.  Moreover, Kaplan argued, a memory test was
more realistic, because consumers look at an ad as long as they need to and
form their impressions during this time period. “Thus, if a student did not
notice the footnote after looking at the advertisement but before being asked
about it, that suggests that the advertisement would be misleading in a real
life scenario.”  Asking specific
questions while the student is reviewing the ad causes them to pay more
attention to the footnote than they otherwise would have.  (Repeating court’s use of singular
“they” because I support it
.) 
 

Screenshot from Themis survey

Another screenshot from Themis survey

Also, the presentation of Themis’ survey emphasized the
disclaimer. As Kaplan’s expert said: “When respondents scrolled down to reach
the question, they were left with a view of the ad that is heavily focused on
the disclaimer. If respondents read the question and then looked back up to the
ad, the disclaimer is the first thing they would see (and possibly the only
part of the ad they would see).” The court found Kaplan’s arguments “highly
probative” (noting in passing that it saw no reason to distinguish a trademark
case accepting Kaplan’s position from a false advertising case).
 
Themis argued that, in any event, the ad was factually true
and facially unambiguous and therefore survey evidence of misleadingness couldn’t
be considered, apparently trying to invoke the Mead Johnson/Havana Club line of cases, but the court noted that
there was no “binding” authority supporting Themis’ argument.  (Also, if you need a footnote to clarify your
claim, your claim is not “facially” unambiguous.)  In any event, Themis failed to establish that
the pass rates were literally true.
 
Themis’ study, however, didn’t suffice to defeat Kaplan’s
motion, because it didn’t test the Themis ad at issue.  “Given this disparity in footnote prominence,
it is possible that a substantial number of the students who correctly answered
the question would not have answered correctly if presented with the much
smaller footnote of the actual Themis Ad at issue here.”  (Which makes my point about facial ambiguity.)  Themis argued that law students were trained
to read “fine print,” especially given the expense of bar prep and the
importance of passing the bar.  (I
routinely ask my students how many of them have read the full agreement between
them and the law school, or them and their landlords.  Spoiler: always some, never a lot.)  Moreover, “[n]o Themis student has ever
complained to Themis that Themis’ advertisements are misleading or deceptive.”  Those arguments were enough to reject Kaplan’s motion for summary judgment.  The court would not hold, as a matter of law,
that law students were unlikely to read footnotes signaled by asterisks “when
evaluating which expensive bar review course to choose to prepare for one of
the most important tests of their lives, especially when there is evidence that
no student has ever complained of being misled.”
 
Kaplan also argued that, even assuming that students read
the footnote, Themis’ ads were still misleading with respect to some
jurisdictions because of a lack of statistical significance.  (I think Kaplan should be arguing about practical significance,
but this is a common lawyers’ problem.)  For
example, Themis advertised that 100% of its students who were first time takers
and completed 75% or more of the course passed the July 2013 Washington D.C.
bar exam, compared to the DC-wide average of 71%. But that 100% pass rate was
based a population of four students, which couldn’t realistically show any
Themis advantage.  The court agreed that
comparing Themis pass rates to state/district-wide averages might imply that
the Themis pass rates were based on a sample size large enough to show significance
(statistical or practical).  A reasonable
jury could go either way.
 

from Blogger http://ift.tt/1WSU3Rd

Posted in Uncategorized | Tagged , | Leave a comment

Foreign marks may be protected in the US under 43(a), Fourth Circuit rules

Belmora LLC v. Bayer Consumer Care AG, No. 15-1335 (4th Cir.
Mar. 23, 2016)
 
Disclosure: I worked on the brief for Belmora, the loser in
this appeal. 
 
Bayer (BCC) registered FLANAX in Mexico for pharmaceutical
products, analgesics, and anti-inflammatories, with sales of naproxen sodium
under the Flanax mark in the hundreds of millions of dollars since 1976.  Some sales come near the US border, but BCC
never sells Flanax in the US and importing it would be against the law.
 

BCC Flanax
Belmora began selling naproxen sodium tablets in the US
under the Flanax mark in 2004, then registered the mark in 2005.  Belmora’s early packaging “closely mimicked”
BCC’s Mexican Flanax packaging in color scheme, font size, and typeface. Though
Belmora changed the packaging, the color scheme, font size, and typeface remain
similar to that of BCC’s Flanax.  In
addition, Belmora made statements “implying that its FLANAX brand was the same
FLANAX product sold by BCC in Mexico,” such as this in a brochure to
prospective distributors:
 
For generations, Flanax has been a
brand that Latinos have turned to for various common ailments. Now you too can
profit from this highly recognized topselling brand among Latinos. Flanax is
now made in the U.S. and continues to show record sales growth everywhere it is
sold. Flanax acts as a powerful attraction for Latinos by providing them with
products they know, trust and prefer.
 

Early Belmora Flanax

Revised Belmora Flanax

Belmora received questions regarding whether it was legal
for Flanax to have been imported from Mexico. And BCC allegedly “identified at
least 30 [purchasers] who believed that the Flanax products . . . were the same
as, or affiliated with, the Flanax products they knew from Mexico.”
 
BCC petitioned the TTAB for cancellation of Belmora’s
registration under Article 6bis of the Paris Convention “as made applicable by
Sections 44(b) and (h) of the Lanham Act” And under § 14(3) of the Lanham Act
because Belmora had used the FLANAX mark “to misrepresent the source of the
goods . . . [on] which the mark is used.”  The TTAB found that Article 6bis isn’t
self-executing, and BCC abandoned this ground on appeal so the court of appeals
didn’t reach it. The TTAB did cancel Belmora’s mark under §14(3), finding that
this wasn’t a close case; the appeal of that cancellation, and BCC’s §43
claims, all ended up before a district court that dismissed all the claims on
the ground that BCC lacked a protectable interest in the Flanax mark in the US.
 
Applying Lexmark,
the court of appeals reversed, holding that “the plain language of § 43(a) does
not require that a plaintiff possess or have used a trademark in U.S. commerce
as an element of the cause of action.” 
Instead, it’s the defendant’s
use in commerce of an offending “word, term, name, symbol, or device” or of a
“false or misleading description [or representation] of fact” “that creates the
injury under the terms of the statute.” 
So BCC had to show that it was likely to be damaged by this use.  “It is important to emphasize that this is an
unfair competition case, not a trademark infringement case.” [Mark McKenna will
be pleased. Although I think it
shouldn’t ultimately matter
, I wonder if the government will pick up on
this panel holding as it relates to Blackhorse;
if §43(a) doesn’t require trademark rights, that implies that cancellation
would not end the Washington team’s federally enforceable rights.]
 
Moreover, the relevant economic harm didn’t have to occur in
the US, because the Lanham Act covers “commerce within the control of Congress,”
and prior Fourth Circuit precedent says that includes “foreign trade.”  “Of course, any such ‘foreign trade’ must
satisfy the Lexmark ‘zone of
interests’ and ‘proximate cause’ requirements to be cognizable for Lanham Act
purposes.”
 
The court of appeals saw this case as relevantly similar to
cases protecting plaintiffs whose mark has become generic against a competitor
who “fail[s] adequately to identify itself as distinct” such that its name
causes “confusion or a likelihood of confusion.”  
 
Likewise, in a “reverse passing
off” case, the plaintiff need not have used a mark in commerce to bring a §
43(a) action. Thus, the plaintiff in a reverse passing off case must plead and
prove only that the work “originated with” him — not that he used the work
(which may or may not be associated with a mark) in U.S. commerce.
 
If use of a mark in US commerce were required for a §43(a)
claim, the genericity and reverse passing off cases couldn’t exist. [After Dastar, the court probably shouldn’t be
saying “work,” since that implies a copyrighted work, not a material object in
which a work is embodied, the only remaining target of a reverse passing off
claim.  So, does the Fourth Circuit now
have a famous foreign marks doctrine, like the Ninth?] 
 
The court of appeals commented that “[a] plaintiff who
relies only on foreign commercial activity may face difficulty proving a
cognizable false association injury under § 43(a). A few isolated consumers who
confuse a mark with one seen abroad, based only on the presence of the mark on
a product in this country and not other misleading conduct by the mark holder,
would rarely seem to have a viable § 43(a) claim.”  [Why? 
Is it the few consumers or the lack of other misleading conduct?  What if it’s a lot of consumers but an
innocent seller?] However, the court of appeals felt differently when there was
alleged intentional passing off in the US “in order to influence purchases by
American consumers,” since “intentional deception can go a long way toward
establishing likelihood of confusion.”
 
Under the circumstances, BCC could bring both false
association and false advertising claims. 
For false association, BCC was within the relevant zone of interest,
given the Lanham Act’s purpose of  “making
actionable the deceptive and misleading use of marks” in “commerce within the
control of Congress.” The complaint alleged that Belmora’s conduct caused BCC
customers to buy Belmora Flanax in the US instead of purchasing BCC’s Flanax in
Mexico. Mexican citizens or Mexican-Americans in border areas might cross into
the US and buy Belmora Flanax here before returning to Mexico, or might forego
purchasing BCC’s Flanax when they visited Mexico because they’d bought the US
Flanax instead.  “Further, by also
deceiving distributors and vendors, Belmora makes its FLANAX more available to
consumers, which would exacerbate BCC’s losses.”  For similar reasons, BCC also alleged
proximate cause.  “BCC may ultimately be
unable to prove that Belmora’s deception ‘cause[d] [these consumers] to
withhold trade from [BCC]’ in either circumstance, but at the initial pleading
stage we  must draw all reasonable
factual inferences in BCC’s favor.”
 
False advertising: Here, BCC and the US company, BHC, both
brought claims under §43(a)(1)(B), which the court of appeals also
reinstated.  BHC (maker of Aleve) brought
a “typical” false advertising claim, as a direct competitor with Belmora in the
US. “If not for Belmora’s statements that its FLANAX was the same one known and
trusted in Mexico, some of its consumers could very well have instead purchased
BHC’s ALEVE brand.”  BCC’s false
advertising claim wasn’t as typical, but still satisfied the zone of interests
test given the Lanham Act’s purpose of “making actionable the deceptive and
misleading use of marks.”
 
Beyond false association, Belmora “parlay[ed]” the Flanax
mark into misleading statements about the product’s “nature, characteristics, qualities,
or geographic origin.” Because its claims regarding popularity, trust, and a
history of quality were “anchored as a factual matter to the FLANAX mark’s
history ‘in the Latino American market,’” they weren’t puffery.
 
The court of appeals cautioned that Belmora owns Flanax as a
mark in the US.  “But trademark rights do
not include using the mark to deceive customers as a form of unfair
competition, as is alleged here.”  An
appropriate remedy might allow Belmora to use the mark, but with measures to
avoid confusion; “any remedy should take into account traditional trademark
principles relating to Belmora’s ownership of the mark,” such as altering the
font and color of the packaging, attaching the manufacturer’s name to the brand
name, or using a disclaimer.
 
The §14(3) cancellation claim was also reinstated. The TTAB
found that the preponderance of the evidence “readily establishe[d] blatant
misuse of the FLANAX mark in a manner calculated to trade in the United States
on the reputation and goodwill of petitioner’s mark created by its use in
Mexico.”  The court of appeals noted that
a cancellation petition can be filed by “any person who believes that he is or
will be damaged . . . by the registration of a mark.”  This language is similar to that interpreted
in Lexmark.  For §14(3), the petitioner must also establish
that the “registrant deliberately sought to pass off its goods as those of
petitioner.”  As with §43, §14(3) didn’t
include a requirement of use in the US.
 
The court of appeals noted that cancellation strips an owner
of “important legal rights and benefits” that accompany federal registration,
but it “does not invalidate underlying common law rights in the
trademark.”  [Note that In re Tam says otherwise, unless Belmora
can re-register once it has purged itself of the misrepresentation, as the
remedy discussion above suggests it may.] 
In a footnote, the court of appeals noted the PTO’s argument that §
14(3) might require a lesser showing of causation because it sets forth an
administrative remedy, whereas the Supreme Court based its Lexmark analysis on common law proximate cause requirements for
judicial remedies. [Again note that In re
Tam
bears on this, not just B&B
v. Hargis
.]

from Blogger http://ift.tt/1MpzfAl

Posted in Uncategorized | Tagged , , | Leave a comment

Amicus brief in Fox v. TVEyes appeal

Arguing that TVEyes’ database and its functions are fair use.  Thanks to the signers, especially Chris Sprigman, & I’m also grateful for the last-minute help of Michael Levy, for when I discovered that being an e-filer in the Second Circuit doesn’t actually make you an e-filer in the Second Circuit unless you have connected your PACER account with your NextGen account, which for some reason requires human intervention.  Lesson learned!

from Blogger http://ift.tt/1UODirf

Posted in Uncategorized | Tagged , | Leave a comment

Inconclusive investigation isn’t enough to give knowledge for contributory TM infringement purposes

Spy Phone Labs LLC v. Google Inc., No. 15-cv-03756-PSG, 2016
BL 86393 (N.D. Cal. Mar. 21, 2016)
 
SPL registered Spy Phone as a mark (for something, I presume),
and submitted its Android app, SPY PHONE Phone Tracker, to Google.  It was downloaded over a million times, and
Google took down a number of competing apps with similar names when SPL requested
that it do so via Google’s online complaint form.  Whenever Google removed an app based on a
trademark complaint, it sent the app developer a notification containing the
complainant’s name and email address.
 
According to the complaint: The app stores information on
phone locations and use on a secure server, and it periodically displays an
icon to let users know the app is running; it’s free, but SPL generates revenue
by running ads via Google on spyphone.com. 
After one developer objected in May 2013, the relationship between
Google and SPL eroded.  SPL submitted a
trademark infringement complaint about another app, “Reptilicus.net Brutal Spy
Phone,” and this time Google said it couldn’t determine the merits of the claim
and refused to act.  Then in June, the
Google Play team removed SPL’s own app, citing violations of Google’s
anti-spyware policy, allegedly despite the fact that SPL’s app complied with
the policy.  Eventually, Google explained
that although none of the functions of SPL’s app violated the anti-spyware
policy, the name itself was unacceptable because it contained the word “spy.”  Though other apps used the same word, Google
promised that it intended to prohibit all developers from doing so in the
future.
 
Thus, SPL decided to drop its lawsuit and relaunch its app
under the name “Phone Tracker.”  In October
2013, Google reinstated SPL’s developer account, but it deleted all the
consumer reviews and records of downloads for SPL’s original app, and the new
app managed only 260,000 downloads in ten months, leading to a steep reduction
in SPL’s advertising revenue.29 Meanwhile, other apps continued to use “spy”  in their names with impunity.  So SPL resumed submitting complaints about
other apps that used “spy” or “SPY PHONE” in their names, but instead of using
the trademark infringement form—which would notify developers of SPL’s identity—SPL
claimed violations of the same anti-spyware policy of which it had fallen
afoul.  In July 2014, SPL made a
complaint about another app from the Reptilicus.net developer, and Google again
suspended SPL’s account without warning, this time for purportedly violating
Google’s spam policy. SPL alleged that its app complied with that policy, but
that the other developer had submitted a false complaint.  This other developer had multiple Play Store
parental monitoring apps—which in itself violates Google’s policies—and several
of these apps contained the word “spy,” or even the phrase “Spy Phone,” in
their names.  SPL allegedly received a
letter from a “concerned” member of the Google Play team “confirming SPL’s
suspicions.”  After this second takedown,
Google searches for the phrase “spy phone” started to list competing apps
before SPL’s website, and the top-listed result is now an app that allegedly
infringes SPL’s trademark.
 
SPL sued the developer, who has not yet been served, and
Google, alleging contributory trademark infringement against Google and
tortious interference against all the defendants. The court first found that
SPL didn’t allege facts sufficient to state a claim for contributory trademark
infringement by Google. With an online marketplace, “a service provider must
have more than a general knowledge or reason to know that its service is being
used to sell counterfeit goods. Some contemporary knowledge of which particular
listings are infringing or will infringe . . . is necessary.”  SPL didn’t allege that Google had notice for
most of the apps; SPL intentionally made spyware complaints instead of
trademark complaints in order to remain anonymous.  “But spyware complaints are not the same as
trademark complaints, and Google could not be expected to respond to a
complaint about one offense by investigating another.”
 
Google also didn’t ignore the initial Reptilicus.net app; it
investigated and responded that it could not assess the merits of the claim.  The app might have used the words “Spy Phone”
simply as a descriptor, as opposed to the distinctive prefix “Reptilicus.net
Brutal,” and that fact would constitute a defense to infringement.  Uncertainty over the existence of
infringement is relevant to an alleged contributory infringer’s knowledge.  That uncertainty, combined with Google’s
investigation and response, made the allegations of knowledge implausible.
 
Nor did tortious interference work, because there was no
allegation that Google committed any act wrongful apart from the interference
itself.

from Blogger http://ift.tt/1PrTyYo

Posted in Uncategorized | Tagged , , | Leave a comment

What’s in a name? A false advertising suit against a generic drug maker

Endo Pharmaceuticals, Inc. v. Actavis, Inc., 2016 WL 1090356,
No. 12-cv-7591 (D.N.J. Mar. 21, 2016)
 
Endo sued Actavis under federal and state law for allegedly
falsely marketing a generic form of oxymorphone hydrochloride extended-release
tablets. The court got rid of the New Jersey consumer protection law claims
because NJ’s law doesn’t protect competitors, but did allow some claims under
the Lanham Act and the New Jersey Fair Trade Act.
 
Endo received FDA approval for an extended release
oxymorphone hydrochloride pain reliever under the brand name Opana ER in 2006;
Actavis received FDA approval for a generic form of that formulation in 2010.  Actavis’ generic is AB rated to Opana ER,
meaning that it’s therapeutically equivalent. 
“Concerned about the potential for abuse of the drug, including the
possibility that persons would crush the pills and snort or inject the powder,
Endo developed a crush-resistant version.” 
The FDA approved this version in 2011. 
Endo stopped making the old version but didn’t recall existing tablets, and
began shipping the new formulation in 2012. 
The new crush-resistant formulation was bioequivalent to the original
formulation of Opana ER and was sold under the same brand name, distinguised as
“Opana ER with Intac.”
 
Endo then filed a Citizen Petition with the FDA, seeking to
have the FDA (1) determine that the old formulation of Opana ER was
discontinued for reasons of safety, (2) refuse to approve any pending generic
approvals for the old formulation, and (3) suspend and withdraw approval for generic
versions of the old formulation. Endo also sued Actavis, arguing that Actavis’s
marketing of “Generic Oxymorphone ER Tablets” as “AB Rated to Opana® ER”’
became misleading after May 2012, once Endo had stopped selling the old
version.  The FDA denied Endo’s petition;
the old formulation wasn’t withdrawn for safety or effectiveness reasons,
because the data did not support the claim that Opana ER with Intac was superior.
 
Actavis argued that Endo was trying an end run around the
FDA’s ruling that approvals of generics AB rated to old Opana ER were okay.  Under Pom
Wonderful
, there is some wiggle room for a false advertising claim not
reliant on interference with FDA decisionmaking.  Endo’s basic argument: “the consumer could
now mistakenly infer (as the consumer could not have before) that Actavis’s
drug is AB rated to Opana® ER with Intac.” 
Can a brand name manufacturer “render the generic manufacturer’s true
advertising misleading and then sue on that basis”?
 
Casting some shade on Endo’s arguments, the court noted that
“Endo itself simultaneously marketed the two versions of the drug for some
months, but of course does not accuse itself of confusing physicians.”  Endo’s scrupulousness in distinguishing
between the two versions, however, posed factual issues not suitable for a
motion to dismiss.
 
On its face, Actavis’s ad said it was AB rated to Opana ER,
which seemed unambiguous and true.  But
since then, Endo argued, there was another formulation of Opana ER, with the
same name, “sort of.”  Thus, Opana ER
might mean two different things, though not too different; because Endo only
makes Opana ER with Intac, consumers might now take Actavis’s claim to be one of
equivalence to Opana ER with Intac.  A doctor
might be misled into thinking there’s just one version of the drug on the
market, but actually there are two. 
 
The court noted that Endo didn’t recall its old Opana ER and
let two versions exist on the market for a while, selling off the old while it ramped
up production of the new.  It took from
February 2012 to after the end of May 2012 for the old inventory to clear the
pipeline and for Endo to stop marketing old Opana ER.  “The FDA apparently found this highly
significant in rejecting Endo’s petition. And Endo in this action will face the
question of how it could keep the two drugs straight in physicians’ minds then,
but can no longer do so now.”
 
The FDA’s rulings about safety tended to undercut the
materiality of the allegedly misleading statements. “Endo’s safety concerns
about Old Opana® ER (which seemed to have crested shortly after it sold off the
last of its inventory) have not been borne out.” And whether doctors ought to
be prescribing one version or another was not a Lanham Act issue, but an FDA
issue.
 
Actavis also argued that it no longer advertised that its
product was AB rated to Opana ER; the complaint’s ads dated from 2011.  This created a factual issue that would also
need to be explored, as did whether Actavis was seeking approval for a crush-resistant
version of its own.  Still, on the
pleadings, this was not a claim ruled out as a matter of law: Endo pled “false
statements about matters the consumer is likely to care about in making a
purchasing choice.”  The court noted that
targeted discovery and an early motion for summary judgment might well be
appropriate.

from Blogger http://ift.tt/1UGASw4

Posted in Uncategorized | Tagged , | Leave a comment

Another poster child for a national anti-SLAPP law: dilution claims against a critic

Doctor’s Data, Inc. v. Barrett, 2016 WL 1086510, No. 10 C
03795 (N.D. Ill. Mar. 21, 2016)
 
Plaintiff DDI sued Dr. Stephen J. Barrett, M.D., the
National Council Against Health Fraud, and Quackwatch for violating §43, as
well as state law claims for defamation and related torts.  Here, the defendants get rid of a number of
claims on summary judgment. DDI is a clinical lab that analyzes urine, blood,
and other samples for health care practitioners; one of its tests is designed
to assess the levels of heavy metals present in a patient’s urine.  Samples are either “provoked” or
“non-provoked”; a provoked sample is one the physician collects after
administering a “chelating agent,” which temporarily increases the patient’s
excretion of heavy metals. DDI uses the same form to report the test results
for both provoked and non-provoked samples. The form reports the heavy metal
levels in the patient’s urine, lists “reference ranges” of typical heavy metal
levels in non-provoked samples, and graphically classifies each of the
patient’s levels as “within reference range,” “elevated,” or “very elevated”
based on those non-provoked reference ranges.
 
Barrett, a retired psychiatrist and consumer advocate,
criticized heavy metal urine testing and DDI’s report form on his websites and
related email listservs. NCAHF and Quackwatch were not-for-profit corporations
that focused on health care consumer advocacy, though they were dissolved by
the time of this opinion.
 
Previously, the court dismissed the Lanham Act claim to the
extent it covered false advertising because DDI lacked standing, but allowed a
claim under §43(c) dilution (!) to proceed. 
(After Lexmark, the standing
argument is probably wrong, but given the context I doubt the defendants’
statements count as commercial speech/commercial advertising or
promotion.)  DDI, however, continued to
press §43(a) false advertising claims, despite the court’s clear earlier
statements; the court construed it as abandoning a federal dilution claim and
the §43 claim was dismissed in its entirety with prejudice.
 
DDI did continue with its claim for trademark dilution under
ITRPA, which provides that the owner of a mark which is famous in Illinois is
entitled to relief “against another person’s commercial use of a mark or
tradename, if the use…causes dilution of the distinctive quality of the
mark.”  This law requires actual
dilution, not merely likely dilution. 
DDI argued that Barrett’s websites were commercial and that defendants
caused dilution by referencing “Doctor’s Data” in the challenged publications
and including DDI’s logo on the first page of one of the publications. But
there was no evidence of dilution of distinctiveness of DDI’s marks.
DDI provided evidence that defendants used its marks, and possibly that DDI’s reputation was damaged by
defendants’ statements using its marks. 
“But causing consumers to think less highly of a trademarked product or
service—even if accomplished through false or misleading statements—is not
equivalent to diluting the distinctiveness of that product or service.
Allegations solely of the former nature point not to trademark dilution but to
defamation and other similar claims.” 
(Something we all knew should be true, but it’s nice to have such a
clear statement in a case.)  Summary
judgment for defendants.
 
Then there is a long, long slog through 85 allegedly
defamatory statements, which I will not inflict on readers who aren’t, like the
court, required to wade through them. 
Basically, Barrett said that “referring patients who have provided
provoked samples to standards applicable to non-provoked tests is highly
misleading and permits unscrupulous physicians and other purported health care
practitioners to convince patients to undergo expensive, but unnecessary,
detoxification treatments,” and the disputes in the case “center primarily on
the extent to which the defendants’ statements assert that Doctor’s Data is a
witting participant in these schemes.” 
The court concluded that, for the most part, the statements that were
most likely to cause reputational harm were about the allegedly scummy doctors
rather than DDI, or appeared in reports protected by the fair report privilege
(e.g., reports of lawsuits filed against DDI and others). Most of the remaining
statements were either true descriptions of the report form or expressions of opinion
about the form. Thus, most of the statements weren’t actionable, though the
court denied summary judgment on a few that might have implicated DDI.
 
For example, Barrett’s description of the DDI report
classifications as misleading (that is, the fact that the form reported the
patient’s provoked levels but only provided unprovoked reference levels for
comparison, and those lower than other labs’) was nonactionable opinion.  The description of the report classification
as misleading was immediately followed by the factual basis for that
evaluation, and Barrett even reproduced a report.  “Misleading” was clearly his opinion.  There is qualifying language at the bottom of
the DDI report that says “[r]eference ranges are representative of a healthy
population under non-challenge or non-provoked conditions.”  While a reasonable jury could find that this
put patients adequately on notice that the reference ranges shown next to the
test results “should be given less weight, or possibly even no weight, if the urine
sample at issue was provoked,” no reasonable jury could find that the report
didn’t make a comparison between provoked results and non-provoked reference
ranges, which was the practice Barrett criticized.
 
Also, here’s a fun discussion:
 
[T]he statement “The provoked urine
toxic metals test is a fraud” does not have a precise and readily apparent
meaning. As an initial matter, the term “fraud” has a broad scope; to speak of
something as a “fraud” may mean it is criminally deceptive, but it may also mean
simply that it is not what it purports to be. When H. L. Mencken famously
opined that “All men are frauds,” he did not incur universal liability for
defamation.  As well, “fraud” is a term
often used as hyperbole, trotted out in even the most inconsequential contexts
…. That the term expressly refers here not to a person, or a knock-off designer
purse, but to a test does nothing to make its meaning more clear; what does it
mean for a test to be a fraud? … [I]f anything, the context here points not to
DDI as the party responsible for “fraud” but to those who use DDI’s test to
deceive the public—that is to say, the physicians who buy DDI’s testing
services.
 
Also, while “shady” is not a factual claim capable of
verification or disproof, describing DDI as a “nonstandard” laboratory might be
defamatory, and the court denied summary judgment on the following statement,
since given more context it might contain some factual claims:  
 
The sample report on DDI’s Web site
includes three pages of measurements and three pages of clinically useless
biochemical tidbits, diagnostic speculations, pseudoscientific blather, and
recommendations for further testing. Unfortunately for patients, amino acid
analysis of urine does not provide basic information about the individual’s
general health, metabolism, nutrient status, or dietary adequacy, and the
supplement recommendations lack a rational basis. It is not possible, for
example, to figure out what people eat by looking at what they excrete. And
finding a substance does not mean that it came from a single source or
metabolic pathway.
 
Tortious interference with prospective economic advantage
claims failed because DDI couldn’t prove a specific enough expectancy of future
business that was disrupted by Barrett’s claims. And tortious interference with
existing contractual relations failed because DDI couldn’t show that a breached
contract resulted from Barrett’s claims, much less that defendants
intentionally induced the breach.  DDI
believed that the relevant doctor’s business collapsed because of Barrett’s
complaints to the Texas medical board and to insurance companies, rendering her
incapable of paying DDI’s bills.  But DDI
didn’t show that Barrett’s complaint caused the doctor’s financial problems or
her failure to pay DDI, or that Barrett complained with the intent to cause a
breach of contract.

from Blogger http://ift.tt/1Shoijx

Posted in Uncategorized | Tagged , , | Leave a comment

One Haas impersonating another is TM infringement, false advertising

Haas Door Co. v. Haas Garage Door Co., No. 3:13 CV 2507, 2016
WL 1047242 (N.D. Ohio Mar. 16, 2016)
 
A family-owned business split, and split a trademark, and
then things went bad.
 
Founded in 1953, Haas Door Sales eventually became Haas Door
Company and Haas Garage Door Company. Haas Door Sales focused exclusively on
retail sales and installation of garage doors; Haas Door Company was incorporated
for the purpose of manufacturing garage doors. 
Haas Garage Door Company took over retail sales; both Haas Door
(manufacturing) and Haas Garage Door (retail sales, installation, and repair)
used the HAAS mark.  In 1989, the owners
sold Haas Door, leaving them with no right to make garage doors, under the HAAS
mark or otherwise, pursuant to a noncompete agreement—though those owners
subsequently retired.  Haas Garage Door
was an authorized dealer of Haas Door, but a dispute arose between the companies
and Haas Door terminated Haas Garage Door’s authorized dealership.  Haas Door has a registration for HAAS for
garage doors and hardware.
 
The court found that the parties each had separate and
distinct rights in the HAAS mark. “The HAAS mark is connected to two
distinctively different goods and services.”  (That strikes me as a bit of an overstatement,
from a consumer perspective—it was not the greatest idea to split them like
that.)
 
While not resolving the core trademark infringement claims
based on HAAS, the court granted partial summary judgment to Haas Door based on
Haas Garage Door’s use of the AMERICAN TRADITIONS SERIES mark, which Haas Door
had used for high end garage doors since 2005. 
Haas Garage Door assembled doors and sold them under the name AMERICAN
TRADITIONS SERIES, using the HAAS mark. 
The court found likely confusion, as well as actual confusion.  An architect was deceived into buying from
Haas Garage Door, “[d]espite doing due diligence and meeting with [Haas Garage
Door] on multiple occasions.”  He was
misled into believing that both Haas Door and Haas Garage Door produced the
same product, but at different locations, and then noticed quality differences
in the door he bought.  Likewise, the
owner of a retail garage door sales, installation, and repair business
mistakenly contacted Haas Garage Door and “was misled into believing he was
engaging in a business relationship where he was obtaining doors directly from
the manufacturer, i.e. Haas Door.”  When
he found out the truth, he ended his relationship with Haas Garage Door.  These events showed likely confusion even
among sophisticated purchasers.
 
In addition, the court found Haas Garage Door liable for
false advertising for using a label on the garage doors that said HAAS GARAGE
DOOR COMPANY [contact info] MANUFACTURERS OF: RESIDENTIAL, COMMERCIAL &
INDUSTRIAL OVERHEAD DOORS & ELECTRIC OPENERS.  Haas Garage Door isn’t a manufacturer, but it
used the label on every door it installed or serviced for years. This was a
literally false claim, so the court presumed actual deception and
materiality.  There was also a causal
link to harm to Haas Door. “This misrepresentation harms Haas Door by depriving
the company of the opportunity to offer customers its products, made to its
standards, policies, and warranties.”

from Blogger http://ift.tt/1ScTLn1

Posted in Uncategorized | Tagged , , | Leave a comment

Porn site’s use of TMs in metatags not confusing

Multifab, Inc. v. ArlanaGreen.com, 122 F. Supp. 3d 1055
(E.D. Wash. 2015)
 
Plaintiff made commercial industrial components and
equipment, and used the name “Multifab” for at least 25 years.  It has the multifabinc.com domain name.
ArlanaGreen.com features pornographic images and videos, and allegedly caused
confusion by using Multifab’s name to promote its services.  Defendants defaulted.  Nonetheless, the court concluded that
Multifab failed to show trademark infringement or false advertising under the
Lanham Act, cyberpiracy under the Anti–Cybersquatting Consumer Protection Act,
or a violation of Washington’s Consumer Protection Act.
 
Infringement: lack of proximity of the goods weighed heavily
against a finding of confusion, as did the degree of consumer care and the
unlikelihood of any expansion into competing territory. “Sales of pornography
and industrial equipment do not target the same class of purchasers in any
discernable way, the products are not similar in use or function, nor are they
complementary in any sense.”  (Insert
your own dirty joke.)  Internet shoppers
are accustomed to trial and error, and Multifab’s goods would be bought by buyers
likely to be familiar with the commercial industrial equipment market, using a high
degree of care. See M2 Software, Inc. v. Madacy Entm’t, 421 F.3d 1073, 1084
(9th Cir. 2005) (because purchasers of music management databases are highly
sophisticated members of the music industry, the possibility that they could be
confused about music management products and services “is almost nil”
regardless of any trademark).  So the
strength of Multifab’s mark (suggestive), the similarity of the parties’ marks
(identical), and defendants’ apparent bad intent favored Multifab, but that
just wasn’t enough given the factors making confusion unlikely.  There was no evidence of actual confusion.
 
False advertising claims failed for the same reasons, as did
state consumer protection law claims.
 
ACPA claims failed because the conduct here didn’t involve
use of a domain name, whether at the top or second level.  Instead, defendants were using metatags and
website content.

from Blogger http://ift.tt/1U1fOAr

Posted in Uncategorized | Tagged , | Leave a comment